Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Drops By 93.3%

Key Points

• Short interest plunged 93.3% to 1,476 shares as of March 31 (from 21,913 on March 15), leaving roughly 0.0% of shares short and a short‑interest ratio of 0.0 days.
• FSNUY traded up 0.2% to $13.10 on Friday; the company has a market cap of $29.51 billion, a P/E of 20.79, and reported quarterly EPS of $0.28 on revenue of $6.94 billion.
• Analysts hold a generally positive view with an average rating of Buy (including Citigroup and Morgan Stanley), and consensus forecasts about $0.79 EPS for the current fiscal year.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) was the target of a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,476 shares, a decline of 93.3% from the March 15th total of 21,913 shares. Approximately 0.0% of the company's shares are short sold. Based on an average daily volume of 164,705 shares, the short-interest ratio is currently 0.0 days.

Fresenius SE & Co. Trading Up 0.2%

Shares of FSNUY traded up $0.03 during trading hours on Friday, reaching $13.10. 41,756 shares of the company traded hands, compared to its average volume of 77,820. The company's fifty day moving average price is $13.94 and its two-hundred day moving average price is $14.31. The company has a market capitalization of $29.51 billion, a price-to-earnings ratio of 20.79 and a beta of 0.81. The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47. Fresenius SE & Co. has a 12 month low of $10.39 and a 12 month high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.28 earnings per share for the quarter. Fresenius SE & Co. had a return on equity of 10.31% and a net margin of 5.71%.The company had revenue of $6.94 billion for the quarter. Equities research analysts predict that Fresenius SE & Co. will post 0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FSNUY has been the subject of a number of analyst reports. Citigroup reissued a "buy" rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy".

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.